Drug Trial Radar · NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
218
Actual
Start
Jun 26, 2019
Primary completion
Jun 30, 2027
Study completion Jul 24, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- Large B-cell Lymphoma
Interventions
Rapcabtagene autoleucel single agentBiological
Single infusion of rapcabtagene autoleucel
IbrutinibDrug
Tablets or capsules for oral daily use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only)Time frame: 28 days
- Phase 1: Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signsTime frame: 24 months
- Phase 1: Tolerability: Ibrutinib dose modifications in the CLL/SLL armTime frame: 24 months
- Phase 1: Manufacture success: Number of patients infused with planned target doseTime frame: 24 months
- Phase 2: Complete Response Rate (CRR) as assessed by local InvestigatorTime frame: 24 months
Locations
37 sites in 8 countries. Site status is shown where the registry gives one.
University of California LA
Los Angeles, California
Stanford University Medical Center
Stanford, California
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois
University of Kansas Cancer Center
Westwood, Kansas
Mass Gen Hosp Cancer Center
Boston, Massachusetts
University of Pennsylvania Clinical
Philadelphia, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
St Davids South Austin Medical Ctr
Austin, Texas
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Sarah Cannon Research Institute
San Antonio, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Salamanca, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Badalona, Barcelona, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.